None listed
Conditions
Interventions
Drug : This study compares the results of clinical adverse events resulting from the use of 1- and 12-month Dual antiplatelet therapy in patients underwent PCI using a bioabsorvable polymer coated dr
Sponsors
The Catholic University of Korea, Seoul St. Mary's Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)Subject must be = 19 years. 2)Patients who underwent percutaneous coronary intervention with Genoss®DES 3)Patients who assigned informed consents and actively participating in this study
Exclusion criteria
Exclusion criteria: 1)The patient has a known hypersensitivity or contraindication to any of the following medications: Heparin, Aspirin, Clopidogrel, Sirolimus, and Contrast media (Patients with documented sensitivity to contrast media which can be effectively premedicated with steroids and diphenhydramine [e.g. rash] may be enrolled. Those with true anaphylaxis to prior contrast media, however, should not be enrolled.) 2)Noncardiac comorbid conditions are present with life expectancy <1 year 3)Patients who have visited the hospital in a cardiogenic shock and are expected to be less likely to survive from the site investigator's medical judgment 4)If the investigator determines that it is not suitable for this clinical trial or may increase the risk associated with participating in this test
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| a composite of Cardiovascular death, Myocardial Infarction, ischemic or hemorrhagic stroke, definite Stent Thrombosis, or Bleeding Academic Research Consortium, BARC) type 3 or 5 bleeding | — |
Secondary
| Measure | Time frame |
|---|---|
| a composite of Cardiovascular death, Myocardial Infarction, ischemic or hemorrhagic stroke, definite Stent Thrombosis, or Bleeding Academic Research Consortium, BARC) type 3 or 5 bleeding;Cardiovascular end point (a composite of Cardiovascular death, Myocardial Infarction, ischemic or hemorrhagic stroke, definite Stent Thrombosis);Bleeding Academic Research Consortium, BARC) type 3 or 5 bleeding;all cause death;cardiac death;all myocardial infarction;ischemic or hemorrhagic stroke;definite or probable stent thrombosis;any revascularization;ischemia-driven target lesion revascularization;target vessel revascularization;Bleeding Academic Research Consortium) type 2 to 5 bleeding.;(Bleeding Academic Research Consortium) type 3, 4, and 5 bleeding;the occurrence of a composite net clinical effects (major adverse cardiac and cerebrovascular events or serious bleeding) and any damage or complications that may have been associated with the procedure | — |
Countries
Korea, Republic of
Contacts
Public ContactJINJU KANG
The Catholic University of Korea, Seoul St. Mary's Hospital
Outcome results
None listed